

Ypsomed Holding AG Brunnmattstrasse 6 PO Box 3401 Burgdorf / Switzerland Tel. +41 34 424 41 11 Fax +41 34 424 41 55 www.ypsomed.com

PRESS RELEASE

Ypsomed concludes Licence Agreement on own auto-injector patents with Cilag GmbH International

Burgdorf, 18 September 2007, 7:00am - Ypsomed is pleased to announce that it has granted to Cilag GmbH International, a non exclusive licence to use certain patents, which protect inventions of Ypsomed, for an auto-injector device for the administration of two biopharmaceutical products with an option to extend the licence for a number of other compounds. Ypsomed is not in a position to communicate the commercial details of the agreement, but expects to receive significant royalties over the term of the contract.

The new agreement is the second non exclusive license agreement Ypsomed has signed with a large pharmaceutical company to use such patents in the area of auto-injector technology.

Richard Fritschi, CEO of Ypsomed, was extremely pleased about the second agreement: "This is a further milestone for Ypsomed and demonstrates how valuable Ypsomed's know-how and the patent portfolio are."

Ypsomed invests more than CHF 25 million annually in research and development of new products and technologies. Today Ypsomed possesses in the area of self-injection devices, pen systems and auto-injector technology more than 220 patent families including both granted and applied patents in numerous countries. Ypsomed owns 40 patent families in the area of auto-injector technology.

Further information is available from Barbara Mischler, Assistant of Investor & Public Relations at Ypsomed Holding AG. Tel. +41 34 424 41 43 or Tel. +41 34 424 41 11. This press release and further documents are available in electronic form at <u>www.ypsomed.com</u>